U.S. Markets closed

Neuralstem, Inc. (CUR)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.15-0.25 (-5.68%)
At close: 4:00PM EDT
People also watch
ATHXCYTXPSTIOSIROPXA

Neuralstem, Inc.

20271 Goldenrod Lane
2nd Floor
Germantown, MD 20876
United States
301-366-4841
http://www.neuralstem.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees10

Key Executives

NameTitlePayExercisedAge
Mr. Richard J. DalyChairman, Chief Exec. Officer, Pres and Interim Principal Financial & Accounting Officer551.67kN/A56
Dr. Karl Y. Johe Ph.D.Co-Founder and Chief Scientific Officer963.33kN/A57
Danielle SpanglerDirector of Investor RelationsN/AN/AN/A
Dr. Thomas G. Hazel Ph.D.Sr. VP of ResearchN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company’s stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Corporate Governance

Neuralstem, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.